Rescue Biomedical announced today that it received a $2.8 million grant from the National Institutes of Health for its opioid overdose treatment. West Lafayette, Indiana received a Fast-Track Small Business Innovation Research, or SBIR, grant from the NIH. The company develops technology that detects when a person is overdosing on an opioid and delivers naloxone […]
Pharmaceuticals
BD names new president of medication delivery
BD (NYSE:BDX) announced today that it named Eric Borin as its president of medication delivery solutions (MDS). Borin, 55, succeeds Rick Byrd in the role. Byrd recently received a promotion to EVP and president of BD’s interventional segment. As president of medication delivery solutions, Borin will report to Mike Garrison, EVP and president of the […]
Corium launches transdermal patch for treating Alzheimer’s
Corium (Nasdaq:CORI) today announced the availability of Adlarity (donepezil transdermal system) for prescription use in the U.S. Adlarity, a once-weekly patch, delivers consistent doses of donepezil through the skin. It treats patients with mild, moderate, or severe dementia of the Alzheimer’s type. It holds FDA approval — the first and only — for 5 mg/day […]
This robotic capsule could deliver large-protein drugs like insulin
Researchers at the Massachusetts Institute of Technology (MIT) developed a new drug capsule with a robotic cap for improved drug delivery. Large-protein drugs generally can’t pass through the mucus barrier that lines the digestive tract. Insulin and most other “biologic drugs” with proteins or nucleic acids thus must be injected or administered in a hospital, […]
Qnovia raises $17M Series A for inhaled therapeutics pipeline
Qnovia announced today that it raised $17 million in a Series A financing to support its inhaled therapeutics technologies. Blue Ledge Capital led the offering. DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures also participated. Los Angeles-based Qnovia develops inhaled therapeutics. It focuses on nicotine replacement therapy (NRT) and cardiopulmonary diseases. Qnovia […]
Pulmatrix completes patient dosing for inhaled migraine treatment
Pulmatrix (Nasdaq:PULM) announced today that all subjects completed dosing in a trial of its orally inhaled migraine treatment. Lexington, Massachusetts-based Pulmatrix is evaluating PUR3100 in a Phase 1 trial using the patented iSperse technology. All subjects completed dosing of the novel orally inhaled formulation of dihydroergotamine (DHE). The company expects Phase 1 data in the […]
Vaxxas receives more than $5 million grant for vaccine delivery patch
Vaxxas announced today the Australian government is granting it nearly $5.5 million for the manufacturing of its vaccine delivery device. Cambridge, Massachusetts-based Vaxxas picked up AU$8.2 million ($5.48 million). The second-round grant represents part of the Australian government’s Modern Manufacturing Initiative (MMI). Funding supports the manufacturing scale-up of Vaxxas’ device for applying vaccines to the […]
Turn Biotechnologies launches delivery system for nucleic acid therapeutics
Turn Biotechnologies announced today that it created a novel platform for the safe and effective delivery of nucleic acid therapeutics. Mountain View, California-based Turn said in a news release that the platform represents a “major expansion” of its business. It designed its eTurna Platform for the next generation of precision medicine. eTurna allows for fine-tuning […]
BD launches next-gen prefillable vaccine syringe
BD (NYSE:BDX) announced today that it launched its next-generation glass prefillable syringe (PFS) for vaccine delivery. Franklin Lakes, New Jersey-based BD’s new Effivax syringe features tightened specifications for processability, cosmetics, contamination and integrity. The company designed it in collaboration with top pharmaceutical firms to meet the evolving needs of vaccine manufacturing. “As biopharmaceutical companies continue […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]